= 1.79 ± 0.05 µM), supporting its targeted anti-angiogenic mechanism. Flow cytometry analysis showed that 7e induced G0/G1 cell cycle arrest and markedly increased apoptotic cell populations. This was further confirmed by upregulation of Bax, Caspase-3, and Caspase-8, alongside downregulation of Bcl-2, indicating activation of both intrinsic and extrinsic apoptotic pathways. Interestingly, 7e inhibited cancer cell migration, suggesting a potential anti-angiogenetic effect. Density functional theory (DFT) calculations revealed that 7e possesses a conjugated electronic system with a suitable frontier orbital distribution, moderate HOMO-LUMO gap, and a favorable electrostatic potential for receptor interaction. Molecular docking and dynamics simulations demonstrated stable binding of 7e within the VEGFR-2 active site, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. MM-GBSA calculations confirmed favorable binding free energy, while per-residue decomposition and protein-ligand interaction fingerprint analysis identified key stabilizing interactions. Essential dynamics and free energy landscape mapping further confirmed a stable and energetically favorable conformational state. ADMET and toxicity predictions indicated acceptable pharmacokinetic properties, low mutagenic risk, and an overall favorable safety profile. Collectively, these findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
Archiv der Pharmazie · مجلد 359 (9) · e70328-e70328
ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
Journal of Computational Biophysics and Chemistry · 1-20
The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.
VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells
BACKGROUND: Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from Streptomyces sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity. METHODS: Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine's binding mode within the DNA-Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via in vitro enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells. RESULTS: aotaphenazine demonstrated a docking binding energy of -19.12 kcal/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of -29.81 kcal/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent π-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC50 of 45.01 nM, comparable to doxorubicin (30.16 nM). In vitro cytotoxicity analysis revealed moderate activity across cancer cell lines (IC50 = 26.30-54.35 µM) and significantly reduced toxicity in normal WI-38 and WISH cells (IC50 = 69.86 µM and 84.72 µM, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2/M population in MDA-MB-231 cells. CONCLUSION: aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.
topoisomerase II inhibitionDNA intercalationanticancer activitynatural product isolation
INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) is a well-established therapeutic target in cancer treatment. In this study, a novel N-phenylacetamide derivative of theobromine, designated as T-1-PA, was designed as a potential semisynthetic EGFR inhibitor. METHOD: The 3D structure, stability, and electronic reactivity of T-1-PA were determined using Density Functional Theory (DFT) analyses. Molecular docking, molecular dynamics (MD) simulations, Molecular Mechanics Generalized Born Surface Area (MM-GBSA), Protein-Ligand Interaction Profiler (PLIP), and Principal Component Analysis of Trajectories (PCAT) were employed to evaluate the binding affinity and inhibitory potential of T-1-PA against EGFR. Computational ADMET profiling was conducted to predict drug-likeness and safety. Subsequently, T-1-PA was semisynthesized and subjected to in vitro biological evaluation. RESULTS: Computational analyses demonstrated a strong binding affinity of T-1-PA to EGFR. The compound exhibited favorable ADMET properties. In vitro assays revealed potent EGFR inhibition with an IC₅₀ of 0.736 ± 0.005 μM. T-1-PA also inhibited the proliferation of HepG2 and MCF7 cancer cell lines with IC₅₀ values of 0.88 ± 0.01 μM and 1.13 ± 0.01 μM, respectively. Flow cytometry analysis indicated induction of apoptosis and G1 phase cell cycle arrest in HepG2 cells. Additionally, T-1-PA significantly impaired HepG2 cell migration and wound-healing capacity. DISCUSSION: The results validate the computational predictions and highlight the anticancer potential of T-1-PA through EGFR inhibition and antiproliferative activity. The compound's favorable pharmacokinetic and safety profiles further support its therapeutic promise. CONCLUSION: T-1-PA is a promising semisynthetic compound with selective antiproliferative activity mediated via EGFR inhibition. These findings encourage further preclinical investigation of T-1-PA as a novel candidate for EGFR-targeted cancer therapy.
A novel sulfamoylphenyl-dihydro-thiadiazole derivative (compound 14) has been designed and synthesized as a dual inhibitor targeting EGFR and human carbonic anhydrases (hCA_IX and hCA_XII). Computational studies, including density functional theory (DFT), molecular docking, and molecular dynamics simulations, confirmed its stability, favorable binding interactions, and reactivity profiles. Compound 14 showed potent inhibition of EGFR (IC₅₀ = 10.12 ± 0.29 nM), hCA_IX and hCA_XII (IC₅₀ = 79 ± 1.2 nM and 58 ± 0.9 nM, respectively). Cytotoxicity assays demonstrated selective activity against cancer cells, with IC₅₀ values of 16.13 µM in MDA-MB-231 and 22.57 µM in MCF-7 cells, compared to 148.32 µM in non-cancerous Vero cells. Compared to acetazolamide, compound 14 exhibited improved selectivity for cancer cells. Apoptosis studies revealed significant cell death in MDA-MB-231 cells, with early and late apoptosis rates of 22.50% and 58.27%, respectively, alongside a marked G1-phase cell cycle arrest (49.10% in treated cells vs. 44.98% in controls). In silico toxicological evaluations indicated a favorable safety profile, with low irritancy and acceptable rat oral LD₅₀ (15.81 mg/kg) and carcinogenic potency (TD₅₀ = 36.95). Compound 14's potent dual inhibition and selective cytotoxicity make it a promising candidate for further optimization and in vivo studies.
BACKGROUND: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles. METHODS: A series of 2,3-dihydro-1,3,4-thiadiazole derivatives was rationally designed, synthesized, and structurally characterized. In vitro cytotoxicity was assessed against MCF-7, HepG-2, HCT-116, and normal WI-38 cells. Mechanistic assays included flow cytometry for cell cycle and apoptosis, and ELISA for caspase-3, Bcl-2, and Bax expression. Molecular docking, 200-ns molecular dynamics (MD) simulations, density functional theory (DFT) calculations, and in silico toxicity profiling supported experimental findings. RESULTS: Compound 11a exhibited the most potent and selective activity (IC₅₀: 9.49 µM for MCF-7, 12.89 µM for HepG-2; SI > 3). It induced >70% apoptosis and dual-phase (S and G2/M) cell cycle arrest. VEGFR-2 inhibition (IC₅₀ = 0.055 µM) was comparable to sorafenib. Computational studies confirmed stable binding at VEGFR-2 active sites. CONCLUSION: Compound 11a is a promising thiadiazole-based candidate with notable in vitro potency, selectivity, and mechanistic activity, supporting its potential for further pharmacokinetics/toxicity evaluation and structural refinement as a VEGFR-2-targeted agent.
VEGFR-2 inhibitorsthiadiazole derivativesanticancer drug discoveryapoptosis induction
Background Thiadiazole-sulfonamide derivatives were synthesized as dual inhibitors of epidermal growth factor receptor (EGFR) and carbonic anhydrase IX (CA-IX) to develop selective anticancer agents.Methods Cytotoxicity was evaluated against MDA-MB-231 and MCF-7 breast cancer cells, with selectivity tested on Vero cells. Enzymatic inhibition studies were conducted against EGFR and CA-IX, using erlotinib and acetazolamide as reference drugs. Apoptosis was assessed through gene expression analysis of BAX/Bcl-2, caspase-8, and caspase-9, alongside flow cytometry for apoptosis and cell cycle analysis. Molecular docking and 200 ns molecular dynamics (MD) simulations evaluated binding interactions. Density Functional Theory (DFT) calculations and in silico ADMET predictions assessed stability, electronic properties, and safety.Results Compound 14 exhibited potent cytotoxicity (IC₅₀ = 5.78 μM, MDA-MB-231; 8.05 μM, MCF-7) and high selectivity (IC₅₀ = 313.08 μM, Vero). It inhibited EGFR (IC₅₀ = 5.92 nM) and CA-IX (IC₅₀ = 63 nM), surpassing reference drugs. Apoptosis induction was confirmed by a 13.97-fold increase in BAX/Bcl-2, caspase upregulation, and G1-phase arrest. Computational analyses confirmed stable binding and favorable safety.Conclusions Compound 14 represents a promising dual EGFR/CA-IX inhibitor with selective anticancer activity. Further in vivo studies are warranted.
EGFR inhibitorscarbonic anhydrase IX inhibitorsanticancer agentsbreast cancer